MSF launches patent opposition database to aid pharmaceutical protestors

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

MSF launches patent opposition database to aid pharmaceutical protestors

Health activists who want to challenge patents given to drugs companies have been given a new tool to make the process easier

Médecins Sans Frontières has today launched a database enabling activists to share information and experiences about opposing patents using one central portal.

The unveiling of the Patent Opposition Database comes 10 years after a landmark decision by Thailand's Central Intellectual Property and International Trade Court to overturn the patent on then-key HIV drug didanosine, after a patent opposition was filed by AIDS Access Foundation and three Thai people living with HIV.

The database contains a searchable listing of 45 patent oppositions relating to key medicines and more than 200 other supporting documents that will aid in the building of future patent oppositions.

In particular it provides a simple guide to legislation covering patent opposition and the processes involved in challenging a patent at the pre-grant or post-grant stage.

It also links to copies of opposition documents that have been filed in countries including Brazil, India and Thailand and calls for users to submit prior art documents that activists in other parts of the world can use for their own opposition applications.

“It’s a myth that every patent application that is filed is valid,” said Michelle Childs, Director of Policy Advocacy for MSF’s Access Campaign. “When you look closely, a patent application may fail one or more of the legal tests it needs to pass. The idea behind this database is to help civil society and patient groups stop unwarranted patents from blocking people’s access to more affordable medicines.”

MSF pointed to a number of cases in which patient groups have already challenged pharmaceutical patents. In India, for example, groups successfully challenged a patent application for the HIV fixed-dose-combination zidovudine/lamivudine on the grounds that it was not a new invention, but simply the combination of two existing drugs.

After that, the Cancer Patient Aid Association filed a pre-grant opposition to an application made by Novartis, which was seeking patent protection for the salt form of imatinib, the active ingredient in its cancer-treating drug Glivec. India’s Supreme Court is now considering whether the country’s patent office was right to refuse to grant Novartis a patent.

more from across site and SHARED ros bottom lb

More from across our site

The firm said major IP developments included advising on a ‘landmark’ deal involving green hydrogen production, as well as two major acquisitions
The appointments follow other recent moves in the European market as firms look to bolster their UPC offerings
Deborah Kirk discusses why IP and technology have become central pillars in transactions and explains why clients need practically minded lawyers
IP STARS, Managing IP’s accreditation title, reveals its latest rankings for patent work, including which firms are moving up
Leaders at US law firms explain what attorneys can learn from AI cases involving Meta and Anthropic, and why the outcomes could guide litigation strategies
Attorneys reveal the trademark and copyright trends they’ve noticed within the first half of 2025
Senior leaders at TE Connectivity and Clarivate explain how they see the future of innovation
A new action filed by Nokia against Asus and a landmark ruling on counterfeits by South Africa’s Supreme Court were also among the top talking points
Counsel explain how they’re navigating patent prosecution matters and highlight key takeaways from Federal Circuit cases
A partner who joined Fenwick alongside two others explains what drew her to the firm and her hopes for growth in Boston
Gift this article